Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents

INTRODUCTION: The prototype DNA hypomethylating agents 5-azacytidine (5AC) and decitabine (DAC) are currently FDA-approved for treatment of blood and bone marrow disorders like myelodysplastic syndrome. 5AC and DAC are considered similar drugs and were shown to induce histone modifications that modu...

Descripción completa

Detalles Bibliográficos
Autores principales: Malkaram, Sridhar A, Shatnawi, Aymen, Fan, Jun, Carraway, Hetty, Denvir, James, Primerano, Donald A, Abd Elmageed, Zakaria Y, Fandy, Tamer E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796079/
https://www.ncbi.nlm.nih.gov/pubmed/35067084
http://dx.doi.org/10.1177/10732748221074051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796079/
https://www.ncbi.nlm.nih.gov/pubmed/35067084
http://dx.doi.org/10.1177/10732748221074051

Ejemplares similares